{"id":13977,"date":"2025-09-05T12:18:56","date_gmt":"2025-09-05T12:18:56","guid":{"rendered":"https:\/\/wpinitiate.com\/echo-test\/demo76e71539\/2025\/09\/05\/biontech-krebsmittel-bnt323-erreicht-wichtigen-meilenstein-richtung-marktreife\/"},"modified":"2025-09-05T12:18:56","modified_gmt":"2025-09-05T12:18:56","slug":"biontech-krebsmittel-bnt323-erreicht-wichtigen-meilenstein-richtung-marktreife","status":"publish","type":"post","link":"https:\/\/wpinitiate.com\/echo-test\/demo76e71539\/2025\/09\/05\/biontech-krebsmittel-bnt323-erreicht-wichtigen-meilenstein-richtung-marktreife\/","title":{"rendered":"Biontech: Krebsmittel BNT323 erreicht wichtigen Meilenstein Richtung Marktreife"},"content":{"rendered":"<p>Biontech hat mit einer seiner Krebsimmuntherapien einen gro\u00dfen Fortschritt in Richtung Marktreife erzielt. Mitgr\u00fcnderin \u00d6zlem T\u00fcreci spricht von einem Meilenstein und will die klinische Entwicklung nun weltweit ausweiten.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Biontech hat mit einer seiner Krebsimmuntherapien einen gro\u00dfen Fortschritt in Richtung Marktreife erzielt. Mitgr\u00fcnderin \u00d6zlem T\u00fcreci spricht von einem Meilenstein und will die klinische Entwicklung nun weltweit ausweiten.<\/p>\n","protected":false},"author":1,"featured_media":13978,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-13977","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/wpinitiate.com\/echo-test\/demo76e71539\/wp-json\/wp\/v2\/posts\/13977","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/wpinitiate.com\/echo-test\/demo76e71539\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/wpinitiate.com\/echo-test\/demo76e71539\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/wpinitiate.com\/echo-test\/demo76e71539\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/wpinitiate.com\/echo-test\/demo76e71539\/wp-json\/wp\/v2\/comments?post=13977"}],"version-history":[{"count":0,"href":"https:\/\/wpinitiate.com\/echo-test\/demo76e71539\/wp-json\/wp\/v2\/posts\/13977\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/wpinitiate.com\/echo-test\/demo76e71539\/wp-json\/wp\/v2\/media\/13978"}],"wp:attachment":[{"href":"https:\/\/wpinitiate.com\/echo-test\/demo76e71539\/wp-json\/wp\/v2\/media?parent=13977"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/wpinitiate.com\/echo-test\/demo76e71539\/wp-json\/wp\/v2\/categories?post=13977"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/wpinitiate.com\/echo-test\/demo76e71539\/wp-json\/wp\/v2\/tags?post=13977"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}